Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

Abstract To date, the development of disease-modifying therapies for Alzheimer’s disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic profiling of patient fluids may help identify novel therapeutic targets and biomarkers associated with AD pathology. H...

Full description

Bibliographic Details
Main Authors: Christopher D. Whelan, Niklas Mattsson, Michael W. Nagle, Swetha Vijayaraghavan, Craig Hyde, Shorena Janelidze, Erik Stomrud, Julie Lee, Lori Fitz, Tarek A. Samad, Gayathri Ramaswamy, Richard A. Margolin, Anders Malarstig, Oskar Hansson
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Acta Neuropathologica Communications
Subjects:
Alzheimer’s disease
Mild cognitive impairment
Biomarker
Proteomics
Inflammation
Apoptosis
Online Access:http://link.springer.com/article/10.1186/s40478-019-0795-2

Internet

http://link.springer.com/article/10.1186/s40478-019-0795-2

Similar Items